查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574311

登革熱疫苗市場：按疫苗類型、最終用戶、年齡層、疫苗開發階段、分銷管道、給藥途徑、技術、患者類型 - 2025-2030 年全球預測

Dengue Vaccine Market by Vaccine Type, End User, Age Group, Vaccine Development Stage, Distribution Channel, Route of Administration, Technology, Patient Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年登革熱疫苗市值為13.8億美元，預計到2024年將達到15.3億美元，複合年成長率為11.79%，到2030年將達到30.2億美元。

全球登革熱疫苗市場被認為在對抗登革熱方面發揮重要作用，登革熱是一種蚊媒熱帶疾病，每年影響數百萬人。預防和治療解決方案均旨在滿足降低登革熱發病率和死亡率的公共衛生要求。由於氣候變遷、都市化和旅行增加，登革熱疫苗在熱帶和亞熱帶地區變得越來越流行，因此對登革熱疫苗的需求顯而易見。應用包括主要針對流行地區青少年和成人的疫苗接種計劃。最終用途包括醫院、診所和公共衛生中心，並有可能擴展到旅遊中心和旅遊中心。

主要市場統計
基準年[2023] 13.8億美元
預測年份 [2024] 15.3億美元
預測年份 [2030] 30.2億美元
複合年成長率（%） 11.79%

有幾個因素正在影響市場的成長，包括人們對蚊媒疾病的認知不斷提高、政府的免疫措施以及減毒活病毒疫苗和重組疫苗等疫苗技術的進步。機會在於刺激東南亞、拉丁美洲和非洲新興市場的需求以及擴大全球疫苗覆蓋範圍。針對各種登革熱病毒血清型的多效價疫苗的開發代表著一個重大機遇，探索口服和經皮等新型給藥系統以提高依從性和可及性也是如此。

挑戰包括安全性和有效性方面的監管障礙，特別是在不同人群和血清型中，這可能會阻礙核准過程。此外，分發疫苗和維持低溫運輸的後勤挑戰構成了真正的障礙。疫苗相對昂貴，這可能會限制低收入地區的疫苗接種，並且需要可擴展的生產和定價策略。

創新研究興趣包括利用 mRNA 和基於載體的技術等尖端平台來開發具有更廣泛血清型覆蓋範圍和更長免疫持續時間的疫苗。此外，探索與蚊蟲控制措施的協同效應並將疫苗納入更廣泛的健康策略將有助於實現更全面的疾病管理。市場的本質是動態的，受到技術進步和不斷變化的流行病學模式的驅動，需要持續的研究和跨部門合作以實現有影響力的健康成果。

市場動態：揭示快速發展的登革熱疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變登革熱疫苗市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球登革熱病例增加，感染地區對疫苗的需求增加
    • 政府和非政府組織採取更多舉措來控制和預防登革熱疫情
    • 生物技術的快速進展促進了更有效的登革熱疫苗的開發
    • 提高大眾對登革熱疫苗接種重要性的認知和教育宣傳活動
  • 市場限制因素
    • 研發和臨床試驗成本高
  • 市場機會
    • 行銷策略的市場開拓旨在提高對登革熱疫苗的認知並將其傳播給高風險人群
    • 建立官民合作關係以資助和加速研究和推廣
    • 使用數位健康工具監測和管理疫苗接種後結果，持續改進
  • 市場問題
    • 疫苗交付的物流問題和疫苗接種猶豫

波特的五力：駕馭登革熱疫苗市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解登革熱疫苗市場的外部影響

外部宏觀環境因素在塑造登革熱疫苗市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解登革熱疫苗市場的競爭狀況

登革熱疫苗市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣登革熱疫苗市場供應商績效評估

FPNV 定位矩陣是評估登革熱疫苗市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製登革熱疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，登革熱疫苗市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球登革熱發生率上升增加了受影響地區對疫苗的需求
      • 政府和非政府組織加強控制和預防登革熱疫情
      • 生物技術的快速進展將加速更有效的登革熱疫苗的開發
      • 提高大眾對登革熱疫苗接種重要性的認知和教育宣傳活動
    • 抑制因素
      • 研發成本和臨床試驗成本不斷上升
    • 機會
      • 制定有針對性的行銷策略，以提高高風險族群對登革熱疫苗的認知和採用
      • 建立官民合作關係以資助和加速研究和分發
      • 利用數位健康工具來監測和管理疫苗接種後的結果，以持續改善。
    • 任務
      • 疫苗交付的後勤問題和對疫苗接種的猶豫
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章登革熱疫苗市場：依疫苗類型

  • 介紹
  • DNA疫苗
  • 去活化疫苗
  • 減毒活疫苗
  • 重組疫苗
  • 次單位疫苗

第7章登革熱疫苗市場：依最終用戶分類

  • 介紹
  • 診所
  • 政府和非政府組織
  • 醫院
  • 研究所

第8章登革熱疫苗市場：依年齡層

  • 介紹
  • 青年
  • 成人
  • 兒科的

第9章登革熱疫苗市場：依疫苗開發階段分類

  • 介紹
  • 臨床試驗
  • 第一階段
  • 第二階段
  • 第三階段
  • 臨床前

第10章登革熱疫苗市場：依分銷管道分類

  • 介紹
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章登革熱疫苗市場：依給藥途徑

  • 介紹
  • 注射
  • 鼻腔
  • 口服

第12章登革熱疫苗市場：依技術分類

  • 介紹
  • 常規疫苗
    • 裂解病毒疫苗
    • 全病毒疫苗
  • 下一代疫苗
    • 類病毒顆粒

第13章登革熱疫苗市場：依病患類型

  • 介紹
  • 有症狀的

第14章美洲登革熱疫苗市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第15章亞太登革熱疫苗市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第16章 歐洲、中東和非洲登革熱疫苗市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第17章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-535C62918799

The Dengue Vaccine Market was valued at USD 1.38 billion in 2023, expected to reach USD 1.53 billion in 2024, and is projected to grow at a CAGR of 11.79%, to USD 3.02 billion by 2030.

The global dengue vaccine market is recognized for its critical role in combating dengue fever, a mosquito-borne tropical disease affecting millions annually. The scope encompasses both prophylactic and therapeutic solutions, addressing the urgent public health need to reduce dengue incidence and mortality. The necessity of the dengue vaccine is underscored by the increasing prevalence of the disease in tropical and subtropical regions, fueled by climate change, urbanization, and increased travel. Applications primarily involve immunization programs targeting adolescents and adults in endemic regions. End-use scope includes hospitals, clinics, and public health centers, with potential expansion into travel centers and tourist hubs.

KEY MARKET STATISTICS
Base Year [2023] USD 1.38 billion
Estimated Year [2024] USD 1.53 billion
Forecast Year [2030] USD 3.02 billion
CAGR (%) 11.79%

Market growth is influenced by several factors, including rising awareness about mosquito-borne diseases, government initiatives for immunization, and advancements in vaccine technologies, such as live attenuated vaccines and recombinant vaccines. Opportunities lie in expanding vaccine coverage globally, stimulating demand across emerging markets in Southeast Asia, Latin America, and Africa. Developing multi-valent vaccines targeting various dengue virus serotypes offers a significant opportunity, as does exploring novel delivery systems, such as oral or transdermal routes, which can enhance compliance and accessibility.

Challenges include regulatory hurdles, particularly concerning safety and efficacy across diverse populations and serotypes, which can impede approval processes. Additionally, logistical issues in vaccine distribution and cold chain maintenance pose practical barriers. The relatively high cost of vaccines can limit access in low-income regions, necessitating scalable production and pricing strategies.

Innovative areas for research include developing vaccines with broader serotype coverage and longer immunity duration, utilizing cutting-edge platforms like mRNA and vector-based technologies. Moreover, exploring synergies with mosquito control initiatives and integrating vaccines into broader health strategies could ensure more comprehensive disease management. The nature of the market is dynamic, driven by technological progress and shifting epidemiological patterns, underscoring the need for continuous research and collaboration across sectors to achieve impactful health outcomes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dengue Vaccine Market

The Dengue Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased global incidence of dengue fever cases leading to higher demand for vaccines in affected regions
    • Growing government and non-governmental organizations' initiatives to control and prevent dengue outbreaks
    • Rapid advancements in biotechnology facilitating the development of more effective dengue vaccines
    • Rising public awareness and education campaigns about the importance of dengue vaccination
  • Market Restraints
    • High R&D and clinical trial costs
  • Market Opportunities
    • Developing targeted marketing strategies to increase awareness and adoption of dengue vaccines among at-risk populations
    • Establishing public-private partnerships to fund and accelerate dengue vaccine research and distribution
    • Utilizing digital health tools to monitor and manage post-vaccination outcomes for continuous improvement
  • Market Challenges
    • Logistical issues in vaccine delivery and vaccine hesitancy

Porter's Five Forces: A Strategic Tool for Navigating the Dengue Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dengue Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dengue Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dengue Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dengue Vaccine Market

A detailed market share analysis in the Dengue Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dengue Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dengue Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dengue Vaccine Market

A strategic analysis of the Dengue Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dengue Vaccine Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca, Bharat Biotech, Bio Farma, Biological E. Limited, CSL Limited, CureVac AG, GeneOne Life Science, Inc., GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., Johnson & Johnson, Medigen Vaccine Biologics Corp., Merck & Co., Inc., Panacea Biotec, PaxVax, Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, and Vabiotech.

Market Segmentation & Coverage

This research report categorizes the Dengue Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Vaccine Type, market is studied across DNA Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, and Subunit Vaccines.
  • Based on End User, market is studied across Clinics, Government and Non-Government Organizations, Hospitals, and Research Institutes.
  • Based on Age Group, market is studied across Adolescent, Adult, and Pediatric.
  • Based on Vaccine Development Stage, market is studied across Clinical Trials, Phase I, Phase II, Phase III, and Pre-Clinical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Route of Administration, market is studied across Injection, Nasal, and Oral.
  • Based on Technology, market is studied across Conventional Vaccines and Next-Generation Vaccines. The Conventional Vaccines is further studied across Split Virus Vaccines and Whole Virus Vaccines. The Next-Generation Vaccines is further studied across Virus-Like Particles.
  • Based on Patient Type, market is studied across Symptomatic.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased global incidence of dengue fever cases leading to higher demand for vaccines in affected regions
      • 5.1.1.2. Growing government and non-governmental organizations' initiatives to control and prevent dengue outbreaks
      • 5.1.1.3. Rapid advancements in biotechnology facilitating the development of more effective dengue vaccines
      • 5.1.1.4. Rising public awareness and education campaigns about the importance of dengue vaccination
    • 5.1.2. Restraints
      • 5.1.2.1. High R&D and clinical trial costs
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing targeted marketing strategies to increase awareness and adoption of dengue vaccines among at-risk populations
      • 5.1.3.2. Establishing public-private partnerships to fund and accelerate dengue vaccine research and distribution
      • 5.1.3.3. Utilizing digital health tools to monitor and manage post-vaccination outcomes for continuous improvement
    • 5.1.4. Challenges
      • 5.1.4.1. Logistical issues in vaccine delivery and vaccine hesitancy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dengue Vaccine Market, by Vaccine Type

  • 6.1. Introduction
  • 6.2. DNA Vaccines
  • 6.3. Inactivated Vaccines
  • 6.4. Live Attenuated Vaccines
  • 6.5. Recombinant Vaccines
  • 6.6. Subunit Vaccines

7. Dengue Vaccine Market, by End User

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Government and Non-Government Organizations
  • 7.4. Hospitals
  • 7.5. Research Institutes

8. Dengue Vaccine Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adolescent
  • 8.3. Adult
  • 8.4. Pediatric

9. Dengue Vaccine Market, by Vaccine Development Stage

  • 9.1. Introduction
  • 9.2. Clinical Trials
  • 9.3. Phase I
  • 9.4. Phase II
  • 9.5. Phase III
  • 9.6. Pre-Clinical

10. Dengue Vaccine Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Dengue Vaccine Market, by Route of Administration

  • 11.1. Introduction
  • 11.2. Injection
  • 11.3. Nasal
  • 11.4. Oral

12. Dengue Vaccine Market, by Technology

  • 12.1. Introduction
  • 12.2. Conventional Vaccines
    • 12.2.1. Split Virus Vaccines
    • 12.2.2. Whole Virus Vaccines
  • 12.3. Next-Generation Vaccines
    • 12.3.1. Virus-Like Particles

13. Dengue Vaccine Market, by Patient Type

  • 13.1. Introduction
  • 13.2. Symptomatic

14. Americas Dengue Vaccine Market

  • 14.1. Introduction
  • 14.2. Argentina
  • 14.3. Brazil
  • 14.4. Canada
  • 14.5. Mexico
  • 14.6. United States

15. Asia-Pacific Dengue Vaccine Market

  • 15.1. Introduction
  • 15.2. Australia
  • 15.3. China
  • 15.4. India
  • 15.5. Indonesia
  • 15.6. Japan
  • 15.7. Malaysia
  • 15.8. Philippines
  • 15.9. Singapore
  • 15.10. South Korea
  • 15.11. Taiwan
  • 15.12. Thailand
  • 15.13. Vietnam

16. Europe, Middle East & Africa Dengue Vaccine Market

  • 16.1. Introduction
  • 16.2. Denmark
  • 16.3. Egypt
  • 16.4. Finland
  • 16.5. France
  • 16.6. Germany
  • 16.7. Israel
  • 16.8. Italy
  • 16.9. Netherlands
  • 16.10. Nigeria
  • 16.11. Norway
  • 16.12. Poland
  • 16.13. Qatar
  • 16.14. Russia
  • 16.15. Saudi Arabia
  • 16.16. South Africa
  • 16.17. Spain
  • 16.18. Sweden
  • 16.19. Switzerland
  • 16.20. Turkey
  • 16.21. United Arab Emirates
  • 16.22. United Kingdom

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2023
  • 17.2. FPNV Positioning Matrix, 2023
  • 17.3. Competitive Scenario Analysis
  • 17.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca
  • 2. Bharat Biotech
  • 3. Bio Farma
  • 4. Biological E. Limited
  • 5. CSL Limited
  • 6. CureVac AG
  • 7. GeneOne Life Science, Inc.
  • 8. GlaxoSmithKline plc
  • 9. Inovio Pharmaceuticals, Inc.
  • 10. Johnson & Johnson
  • 11. Medigen Vaccine Biologics Corp.
  • 12. Merck & Co., Inc.
  • 13. Panacea Biotec
  • 14. PaxVax, Inc.
  • 15. Pfizer Inc.
  • 16. Sanofi
  • 17. Serum Institute of India Pvt. Ltd.
  • 18. Sinovac Biotech Ltd.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Vabiotech

LIST OF FIGURES

  • FIGURE 1. DENGUE VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. DENGUE VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DENGUE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DENGUE VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DENGUE VACCINE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DENGUE VACCINE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. DENGUE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. DENGUE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DENGUE VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DENGUE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DENGUE VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DENGUE VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DENGUE VACCINE MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DENGUE VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DENGUE VACCINE MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DENGUE VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DENGUE VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DENGUE VACCINE MARKET SIZE, BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DENGUE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DENGUE VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DENGUE VACCINE MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DENGUE VACCINE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DENGUE VACCINE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DENGUE VACCINE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DENGUE VACCINE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DENGUE VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DENGUE VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DENGUE VACCINE MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DENGUE VACCINE MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DENGUE VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DENGUE VACCINE MARKET SIZE, BY SPLIT VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DENGUE VACCINE MARKET SIZE, BY WHOLE VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL DENGUE VACCINE MARKET SIZE, BY VIRUS-LIKE PARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL DENGUE VACCINE MARKET SIZE, BY SYMPTOMATIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 322. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 324. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 330. NIGERIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 331. NIGERIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 332. NIGERIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 333. NIGERIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 334. NIGERIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 335. NIGERIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 338. NIGERIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 340. NORWAY DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 341. NORWAY DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 342. NORWAY DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 343. NORWAY DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 344. NORWAY DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 345. NORWAY DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 348. NORWAY DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 350. POLAND DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 351. POLAND DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 352.